Early Identification of Toxicity & Responses to BCMA CAR-T Therapy in RRMM | Kai Rejeski, MD |#ASH24

Early Identification of Toxicity & Responses to BCMA CAR-T Therapy in RRMM | Kai Rejeski, MD |#ASH24
CAR-T Efficacy for Myeloma Patients with Bispecific Exposure | Johannes Waldschmidt, MD | #ASH24
CAR-T Efficacy for Myeloma Patients with Bispecific Exposure | Johannes Waldschmidt, MD | #ASH24
Minority Access & Outcomes with Anti-BCMA CAR T Therapy in Myeloma
New Insights for Amyloidosis in Myeloma | Suzanne Lentzsch, MD | #ASH24
New Insights for Amyloidosis in Myeloma | Suzanne Lentzsch, MD | #ASH24
What are the precursor conditions of multiple myeloma?